# Jiangsu Qihao Medical Technology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/jiangsu-qihao-medical-technology

- Industry: Medical Devices & Equipment
- Headquarters: Nantong, China
- Website: www.breathbest.com
- Latest round: Series C (Nov 7, 2023)
- Investors on record: 7

## About

Established in 2017 and based in Jiangsu, China, Jiangsu Qihao Medical Technology is a medical equipment company that provides medical device for otolaryngology field. In November 2023, the firm raised series C funding from new investors CAS Advanced Research Institute Fund, Xinhua Holding Group, returning investors Anhui Guoyao Venture Capital Management, Huaying Investment, and Baidu Ventures.

Jiangsu Qihao Medical Technology focuses on the research and development of medical device. The company's products includes low-temperature plasma surgery system, fully degradable sinus drug stent system and degradable expansion hemostatic sponge. The company provides its products to many hospitals such as Shanghai Children's Hospital and PLA General Hospital.

## Funding rounds

- Series C, Nov 7, 2023 — Baidu Ventures, Huaying Investment, Anhui Guoyao Venture Capital Management, CAS Advanced Research Institute Fund, Xinhua Holding Group
- Series B, Nov 15, 2021 — Baidu Ventures, Huaying Investment, Yunsong Capital
- Series A, Dec 10, 2020 — Huaying Investment, Anhui Guoyao Venture Capital Management, Hefei State-Owned Assets Holding

## Investors

- Huaying Investment (https://capitalatlas.ai/funds/huaying-investment) — Series A, Series B, Series C
- Anhui Guoyao Venture Capital Management (https://capitalatlas.ai/funds/anhui-guoyao-venture-capital-management) — Series A, Series C
- Hefei State-Owned Assets Holding (https://capitalatlas.ai/funds/hefei-state-owned-assets-holding) — Series A
- Baidu Ventures (https://capitalatlas.ai/funds/baidu-ventures) — Series B, Series C
- Yunsong Capital (https://capitalatlas.ai/funds/yunsong-capital) — Series B
- CAS Advanced Research Institute Fund — Series C
- Xinhua Holding Group — Series C